---
title: "AstraZeneca Phase 3 ATTR-CM Trial Fails; FDA Ruling Ends GLP-1 Shortage Claims"
id: "stat-news-3-stat-pharmalittle-we-re-reading-about-an-astrazeneca-trial-failure-a-monstrous"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-3-stat-pharmalittle-we-re-reading-about-an-astrazeneca-trial-failure-a-monstrous"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/08/28/astrazeneca-trial-failure-monstrous-conflict-of-interest/?utm_campaign=rss"
published_at: "2026-08-28T13:04:02.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# AstraZeneca Phase 3 ATTR-CM Trial Fails; FDA Ruling Ends GLP-1 Shortage Claims
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-3-stat-pharmalittle-we-re-reading-about-an-astrazeneca-trial-failure-a-monstrous
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/08/28/astrazeneca-trial-failure-monstrous-conflict-of-interest/?utm_campaign=rss)
- **Published At:** 2026-08-28T13:04:02.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- STAT reported that **AstraZeneca** disclosed a surprise failure of a Phase 3 clinical trial in patients with transthyretin amyloid cardiomyopathy (**ATTR-CM**). The company said its investigational agent, described as a **silencer**, provided no added benefit in patients already taking a **stabilizer** medicine. This interaction was sufficiently strong to undermine the entire study. - The trial targeted a progressive heart condition (ATTR-CM) and was closely watched given the multibillion-dollar market for related therapies. AstraZeneca’s post hoc explanation emphasized the lack of incremental benefit when the silencer was administered on top of stabilizer therapy. - Separately, Bloomberg Law coverage noted a U.S. appeals court found the **FDA** followed proper procedures when declaring that several diabetes and obesity medicines from Novo Nordisk and Eli Lilly were no longer in shortage. That decision curbed large-scale compounders’ ability to mass-produce alternatives to branded **GLP-1** drugs after the shortage declarations ended. - The STAT item also referenced other reporting available behind a STAT+ paywall, including additional context on the AstraZeneca failure and other industry developments; full details were not reproduced in the free excerpt. - The article contained background about Pharmalot’s newsletter and columnist Ed Silverman, and it noted that some items in the piece are accessible only to STAT+ subscribers. Details not present in the free excerpt — such as numerical trial outcomes, drug names beyond the generic descriptors, timelines, or specific regulatory documents — were not reported in the source provided.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/pharmalot/2026/08/28/astrazeneca-trial-failure-monstrous-conflict-of-interest/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/08/28/astrazeneca-trial-failure-monstrous-conflict-of-interest/?utm_campaign=rss) [Physicians](https://www.statnews.com/topic/physicians/) [FDA](https://www.statnews.com/topic/fda/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) # Pharmalittle: We’re reading about an AstraZeneca trial failure, a ‘monstrous’ conflict of interest, and more ## The FDA approved a new medicine from Roivant to treat dermatomyositis, a rare autoimmune disease * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/08/28/astrazeneca-trial-failure-monstrous-conflict-of-interest/?utm_campaign=rss) ![an anthropomorphized red and blue pill illustrated in the style of the famous american gothic painting](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg) Alex Hogan/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Aug. 28, 2026 Pharmalot Columnist, Senior Writer ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") 2. [](https://x.com/Pharmalot "X") ed.silverman@statnews.com Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). And so, another working week will soon come to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still taking shape, but we plan on promenading with the official mascots, catching up on our reading, escorting Mrs. Pharmalot to a speakeasy and, if time permits, holding another listening party, where the rotation will likely include [this](https://youtu.be/b7hyuhsAW54?si=1tmB0u_DdWhxTSZV), [this](https://youtu.be/e8ftD3Qlq-c?si=pWHs_hSpUWRcB9f8), [this](https://youtu.be/GZ_g84xH3eg?si=Dk70yKBKd4A0nUsV), [this](https://youtu.be/ttKhwrgpBso?si=el_AR_7V3Pz_S-3B) and [this](https://youtu.be/_yyiDyFsG5o?si=cyrXI3NXLgGVs962). And what about you? The end of summer is nigh, but there is still opportunity to make your way to a beach, hike some trails and paddle about lakes. You can fuss about the kitchen and make a favorite dish or finish that stack of books taking up space. Or maybe this is a moment to simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you in a week and a half, since we will be on a brief respite. Never fear, though, we have a stable of pinch hitters who will bring you Pharmalittle each day… **AstraZeneca detailed the surprise failure of a closely watched heart disease clinical trial, laying out how its experimental drug offered no additional benefits for patients who were largely already on another type of medicine, the latest twist in a multibillion dollar market** , [STAT](https://www.statnews.com/2026/08/28/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam/) explains. The study indicated that patients with a progressive condition known as ATTR-CM who received AstraZeneca’s drug, what’s called a silencer, saw no improvements if they were already taking another type of drug called a stabilizer, an effect so powerful that it tanked the whole Phase 3 study. Advertisement **A U.S. appeals court ruled the Food and Drug Administration went through the proper process when it declared Novo Nordisk and Eli Lilly’s diabetes and obesity drugs are no longer in shortage** , [Bloomberg Law](https://news.bloomberglaw.com/health-law-and-business/fda-drugmakers-defeat-compounders-in-fight-over-glp-1-shortage) notes. The order is a loss for the Outsourcing Facilities Association, which representing large-scale compounders and challenged FDA decisions in the last two years that shortages ended for Novo’s Ozempic and Wegovy and Lilly’s Mounjaro and Zepbound. That declaration restricted compounders from legally mass-producing versions of the drugs. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [pharmalittle](https://www.statnews.com/topic/pharmalittle/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Pharmalot Columnist, Senior Writer 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-1317445583-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In autopsy of failed heart disease study, AstraZeneca raises broader questions about silencer drugs](https://www.statnews.com/2026/08/28/astrazeneca-ionis-wainua-eplontersen-attr-cm-study-failure-bridgebio-alnylam/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-457163926-80x80.jpg) [We quit the CDC last year. The problems we protested remain](https://www.statnews.com/2026/08/28/cdc-protest-resignations-one-year-later-houry-jernigan-daskalakis/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/marc-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Former Stanford president releases emails to rebut fraud and cover-up allegations in new book](https://www.statnews.com/2026/08/27/marc-tessier-lavigne-responds-theo-baker-book-misconduct-stanford-genentech/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/Bolner01-80x80.jpg) [A state gave sheriffs 20% of its opioid settlement cash. We followed the money](https://www.statnews.com/2026/08/27/opioid-settlement-funds-enforcement-or-treatment-louisiana-sheriff-investigation/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_998225050-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [The mystery of Moderna’s magic algorithm](https://www.statnews.com/2026/08/27/moderna-merck-cancer-vaccine-secret-ingredient-an-algorithm/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/image-15-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside Moderna and Merck’s cancer vaccine triumph](https://www.statnews.com/2026/08/24/inside-moderna-and-merck-cancer-vaccine-triumph/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/Revmed_campus2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves new pancreatic cancer drug expected to usher in new era of treatment](https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AP26111614763455-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [HHS document offers new clues to Kennedy’s vaccine plans](https://www.statnews.com/2026/08/21/rfi-reveals-possible-kennedy-strategy-vaccine-policy-changes/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/F0372048-Lipoprotein_A_particle_illustration-1-e1787689211295-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [New treatments for common cardiovascular risk factor near the market, with billions at stake](https://www.statnews.com/2026/08/26/lp-a-drugs-novartis-amgen-lilly-potential-heart-disease-blockbuster/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2270934863-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Comments on OMB research rule mysteriously removed from federal website](https://www.statnews.com/2026/08/25/russell-vought-omb-funding-comments-daughter-benefited-nih-research/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 27, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more ](https://www.statnews.com/pharmalot/2026/08/27/pancreatic-cancer-drug-approved-trump-deal-with-biotechs/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 26, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more ](https://www.statnews.com/pharmalot/2026/08/26/gsk-shingles-shot-us-employers-dropping-glp1-coverage/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 25, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Turkish antitrust authorities probe Teva for allegedly gaming the patent system, disparaging rival drugs ](https://www.statnews.com/pharmalot/2026/08/25/turkish-authorities-probe-teva-gaming-patent-system-disparaging-rivals/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 25, 2026 ### ![](https://
## Related Clinical Research

- [Pacibekitug, an IL-6 antibody, lowered inflammation in Phase 2 TRANQUILITY — implications for hear](https://medichelpline.com/clinical-feed/stat-news-0-stat-a-novartis-drug-cut-inflammation-can-it-improve-heart-outcomes.md)
- [AstraZeneca and Ionis Explain Unexpected Failure of Heart-Disease Drug as Alnylam Watches](https://medichelpline.com/clinical-feed/stat-news-1-stat-astrazeneca-and-ionis-detail-surprise-failure-of-heart-disease-drug-with.md)
- [Sprint intervals boost heart-protective proteins more than moderate cycling, study finds](https://medichelpline.com/clinical-feed/medical-news-today-0-sprints-or-endurance-study-finds-short-workouts-release-heart-protective.md)
- [Which Exercises Best Target Blood Pressure, Blood Sugar, and Cholesterol in Metabolic Syndrome?](https://medichelpline.com/clinical-feed/medical-news-today-0-how-do-different-exercises-target-blood-pressure-blood-sugar-and-cholesterol.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.